{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T18:17:41Z","timestamp":1781979461420,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":736,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.rmed.2021.106556","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T03:06:13Z","timestamp":1628046373000},"page":"106556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6127-2486","authenticated-orcid":false,"given":"Andrea","family":"Portacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Diaferia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Santomasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1563-6864","authenticated-orcid":false,"given":"Silvano","family":"Dragonieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esterina","family":"Boniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2021.106556_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06033-2","article-title":"COVID-19 pneumonia: different respiratory treatments for different phenotypes?","author":"Gattinoni","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.rmed.2021.106556_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2146","article-title":"Predictors of COVID-19 severity: a literature review","author":"Gallo Marin","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.rmed.2021.106556_bib3","series-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China","author":"Wang","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib4","series-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","author":"Zhou","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2021.106556_bib6","article-title":"Predictors of COVID-19 severity: a literature review [Internet]","volume":"vol. 31","author":"Gallo Marin","year":"2021"},{"key":"10.1016\/j.rmed.2021.106556_bib7","series-title":"Immunopathology of Galectin-3: an Increasingly Promising Target in COVID-19. F1000Research","author":"Velpula","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib8","series-title":"A Potential Role for Galectin-3 Inhibitors in the Treatment of COVID-19","author":"Caniglia","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.03.008","article-title":"Galectins: multitask signaling molecules linking fibroblast, endothelial and immune cell programs in the tumor microenvironment","author":"Elola","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.rmed.2021.106556_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/glycob\/cwy001","article-title":"Galectin-3 and cancer stemness","author":"Nangia-Makker","year":"2018","journal-title":"Glycobiology"},{"key":"10.1016\/j.rmed.2021.106556_bib11","series-title":"The many roles of galectin-3, a multifaceted molecule, in innate immune responses against pathogens","author":"D\u00edaz-Alvarez","year":"2017"},{"key":"10.1016\/j.rmed.2021.106556_bib12","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-\u03b21-driven lung fibrosis by galectin-3","author":"MacKinnon","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2021.106556_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1096-9896(199607)179:3<309::AID-PATH572>3.0.CO;2-D","article-title":"Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis","author":"Kasper","year":"1996","journal-title":"J. Pathol."},{"key":"10.1016\/j.rmed.2021.106556_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2019.09.005","article-title":"The role of galectins in virus infection - a systemic literature review","author":"Wang","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.rmed.2021.106556_bib15","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell [Internet]. 2020 Apr 16 [cited 2021 Jul 10];181(2):271. Available from:\/pmc\/articles\/PMC7102627\/.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"10.1016\/j.rmed.2021.106556_bib16","series-title":"Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein","author":"Behloul","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02069","article-title":"Hyperinflammation and fibrosis in severe COVID-19 patients: galectin-3, a target molecule to consider","author":"Garcia-Revilla","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.rmed.2021.106556_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-065X.2009.00790.x","article-title":"Galectins in innate immunity: dual functions of host soluble \u03b2-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs)","author":"Sato","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.rmed.2021.106556_bib19","series-title":"Single-Cell Analysis Reveals Macrophage-Driven T Cell Dysfunction in Severe COVID-19 Patients","author":"Liu","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia","author":"De Biasi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.rmed.2021.106556_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/JLB.3COVR0520-272R","article-title":"Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts","author":"Wang","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.rmed.2021.106556_bib22","doi-asserted-by":"crossref","DOI":"10.7883\/yoken.JJID.2021.020","article-title":"Assessment of galectin-1, galectin-3, and PGE2 levels in patients with COVID-19","author":"Kazancioglu","year":"2021","journal-title":"Jpn. J. Infect. Dis."},{"key":"10.1016\/j.rmed.2021.106556_bib23","article-title":"Acute respiratory distress syndrome: the Berlin definition","author":"Ranieri","year":"2012","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.rmed.2021.106556_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.rmed.2021.106556_bib25","volume":"vol. 144","author":"Tjendra","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.09.018","article-title":"IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study","author":"Galv\u00e1n-Rom\u00e1n","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2021.106556_bib27","volume":"vol. 323","author":"Wu","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib28","series-title":"Prognostic value of C-reactive protein in patients with coronavirus 2019","author":"Luo","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib29","article-title":"Circulating galectin-3 in infections and non-infectious inflammatory diseases","author":"Ten Oever","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.rmed.2021.106556_bib30","volume":"vol. 25","author":"Chen","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib31","author":"Tuegel"},{"key":"10.1016\/j.rmed.2021.106556_bib32","series-title":"The Predictive Value of Plasma Galectin-3 for Ards Severity and Clinical Outcome","author":"Xu","year":"2017"},{"key":"10.1016\/j.rmed.2021.106556_bib33","article-title":"COVID-19- versus Non-COVID-19-related Acute Respiratory Distress Syndrome: Differences and Similarities [Internet]","volume":"vol. 202","author":"Brault","year":"2020"},{"key":"10.1016\/j.rmed.2021.106556_bib34","series-title":"Respiratory Physiology of COVID-19-Induced Respiratory Failure Compared to ARDS of Other Etiologies","author":"Grieco","year":"2020"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121002626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121002626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:22:08Z","timestamp":1760617328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611121002626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":34,"alternative-id":["S0954611121002626"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106556","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106556"}}